Nina A. Hilkens
Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets
Hilkens, Nina A.; Algra, Ale; Diener, Hans-Christoph; Reitsma, Johannes B.; Bath, Philip M.; Csiba, Laszlo; Hacke, Werner; Kappelle, L. Jaap; Koudstaal, Peter J.; Leys, Didier; Mas, Jean-Louis; Sacco, Ralph L.; Amarenco, Pierre; Sissani, Leila; Greving, Jacoba P.
Johannes B. Reitsma
Philip M. Bath
L. Jaap Kappelle
Peter J. Koudstaal
Ralph L. Sacco
Jacoba P. Greving
Objective: To develop and externally validate a prediction model for major bleeding in patients with a TIA or ischemic stroke on antiplatelet agents.
Methods: We combined individual patient data from 6 randomized clinical trials (CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT, and PRoFESS) investigating antiplatelet therapy after TIA or ischemic stroke. Cox regression analyses stratified by trial were performed to study the association between predictors and major bleeding. A risk prediction model was derived and validated in the PERFORM trial. Performance was assessed with the c statistic and calibration plots.
Results: Major bleeding occurred in 1,530 of the 43,112 patients during 94,833 person-years of follow-up. The observed 3-year risk of major bleeding was 4.6% (95% confidence interval [CI] 4.4%–4.9%). Predictors were male sex, smoking, type of antiplatelet agents (aspirin-clopidogrel), outcome on modified Rankin Scale ≥3, prior stroke, high blood pressure, lower body mass index, elderly, Asian ethnicity, and diabetes (S2TOP-BLEED). The S2TOP-BLEED score had a c statistic of 0.63 (95% CI 0.60–0.64) and showed good calibration in the development data. Major bleeding risk ranged from 2% in patients aged 45–54 years without additional risk factors to more than 10% in patients aged 75–84 years with multiple risk factors. In external validation, the model had a c statistic of 0.61 (95% CI 0.59–0.63) and slightly underestimated major bleeding risk.
Conclusions: The S2TOP-BLEED score can be used to estimate 3-year major bleeding risk in patients with a TIA or ischemic stroke who use antiplatelet agents, based on readily available characteristics. The discriminatory performance may be improved by identifying stronger predictors of major bleeding.
Hilkens, N. A., Algra, A., Diener, H., Reitsma, J. B., Bath, P. M., Csiba, L., …Greving, J. P. (2017). Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets. Neurology, 89(9), https://doi.org/10.1212/WNL.0000000000004289
|Journal Article Type||Article|
|Acceptance Date||May 1, 2017|
|Online Publication Date||Aug 2, 2017|
|Publication Date||Aug 29, 2017|
|Deposit Date||Jan 24, 2018|
|Publicly Available Date||Aug 3, 2018|
|Publisher||American Academy of Neurology|
|Peer Reviewed||Peer Reviewed|
Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets S2TOP-BLEED.pdf
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf
You might also like
Stroke outcome related to initial volume status and diuretic use
External validation of e-ASPECTS software for interpreting brain CT in stroke